Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Draupnir Bio

Draupnir Bio's headquarters in Risskov, Denmark

Description

People (6)

Casper Tind Hansen

Joachim Pold Vilstrup

Simon Glerup

Amanda Simonsen

Casper Larsen

Marianne Lundsgaard Kristensen

Jobs